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Introduction
Psychotropic medications use other than stimulants have not been adequately studied in children in terms of benefit and safety. Their use in children is mostly based on extrapolation of information from adult studies [1] . There is a growing preference for the use of psychotropic medications over other non-pharmacological interventionsin child and adolescent mental care [1] [2] [3] . Factors majorly responsible for this preference include severity or type of psychiatric disorder, the need for quick symptom relief and lack of multidisciplinary care, particularly in the low resourced countries [1, 2] . Patterns of prescribing and the choice of psychotropic medications vary in different settings [4] . Whilst newer agents and rational prescribing (justifiable use) are favored in specialized settings [1] [2] [3] 5] , the pattern remains largely unclear in settings without specialized care units for children, mainly due to lack of data [6] . In
Europe and America for instance, where specialized child and adolescent health care services are available, psychosocial management is more preferred, especially for mild to moderate conditions [1] [2] [3] 5] . Newer agents such as Risperidone, olanzapine, fluoxetine are preferred to older ones like haloperidol and amitriptyline [1, 2, 7] . Nonetheless, they have also reported increase in rate of off-label use of psychotropic medications (psychotropic prescription outside its approved indications) [2, 7, 8] and polypharmacy among children and adolescent in these centers [2, [9] [10] [11] . Studies conducted in Africa among adult population, though scanty, have likewise shown a high rate of off-label use of psychotropics low preference for newer agents due to cost and polypharmacy [12, 13] . It is however not clear the extent to which these apply to children and adolescents in centers without specialized care. Botswana spends about 5.8% of its Gross Domestic Product (GDP) on health and provides free medical for all the citizens, but only one percent of its total health budget goes to mental health care [14] . It operates three tiers of health care system (primary, secondary and tertiary), with mental health being part of all levels but has only one mental referral (tertiary) hospital which majorly provides services for adult and some children with mental conditions. Child and adolescent services are thus being provided by general adult mental specialists who are currently less than 10 in a population of 2.1 million people [15] and no evaluation of the effectiveness of psychopharmacological therapies currently on offer has been done. We therefore decided to conduct a treatment audit in the mental tertiary hospital in Botswana, which is a non-specialized child and adolescent care setting, and see how it conforms to rational drug prescription pattern in the developed countries. It was also hoped that the findings of this study would lay a foundation for biomedical research in pediatric mental health prescribing in this setting.
Methods
We conducted a retrospective audit of 238 children and adolescents who attended Sbrana psychiatric hospital (SPH) from the first of January, 2012 when the hospital record could easily be accessed to the thirty-first of July, 2016 when we decided to conduct this audit. tricyclic antidepressant was given to 12(70.6%) patients, selective serotonin re-uptake inhibitor was used in by the remaining 5(29.4%) ( Table 3 ). Anticonvulsants (25%) which include Sodium valproate and carbamazepine were prescribed majorly for epilepsy and a few cases of bipolar. Benzodiazepines was administered to 14(11.6%) patients for sleep related problems, while promethazine as pro re nata was administered to 3(2.5%) patients during in-patient care ( Table 2 ).
The rate of 'off-label' prescribing among 48 who had antipsychotic medication (measured by use for unlicensed purposes) was 54.2%.
Discussion
The current study presented a collection of data about the prescribing pattern among children and adolescents from a national mental hospital in Botswana. Being the only mental referral hospital in the country, the study provided an invaluable overview of psychotropic use among children with mental disorders in Botswana. The rate of non-pharmacological (49.5%) interventions such as counselling, family work, educational and occupational therapy intervention, is consistent with relevant literature [2, 3, 5, 16] . Antipsychotics were the most prescribed psychotropics (40%), either as a monotherapy or combined. Unlike a study conducted among adult patients in Nigeria [12, 13] , where the use of the newer agents are less favored due to cost, atypical agents were more prescribed, with risperidone, olanzapine and quetiapine accounting for 68.8% of all antipsychotics.
The current practice of child and adolescent mental care in our setting despite the shortage of specialists still follows the trend of atypical antipsychotic preference over the conventional ones as in the developed countries [2, 5, 16] . This is made possible by the fact that government is responsible for most of the healthcare funding, with free health care at all levels in Botswana and only about 5% being out of pocket [14] . Although atypical medications have not been adequately studied among children [2, 3] , they have been recommended for use by the National Institute for Health and Care
Excellence (NICE) guideline as first line in the treatment of psychosis in the pediatric population [17] . When used cautiously, they are associated with less risk of extrapyramidal side effects (EPSE), albeit their use should be balanced against the risk of significant metabolic effects [18] . Of the two commonly prescribed atypical antipsychotics in our setting; olanzapine and risperidone, the latter is preferred as the first line medication for psychosis or any other disorder for which antipsychotics are prescribed. This agrees with reports that risperidone is the most prescribed of all the second generation antipsychotics in children with psychotic conditions [2, 19, 20] .
Moreover, metabolic side effects such as weigh gain, dyslipidemia to which children may be more vulnerable than their adult counterparts, are more associated with olanzapine [21] . [18] . Antipsychotic prescription outside its approved indications (off-label) was remarkable among others, accounting for 54.2% of its use and is comparable to a report from more specialized child care setting [2] , thus suggesting that the practice is not restricted to settings without specialized care. The practice of using medications outside their licensed indications was previously known in adult; it is currently becoming a common practice in pediatric population [7, 24] . Disorders such CD and hyperkinetic disorder, which are externalizing in nature, are often misdiagnosed as psychotic disorders thus informing the use of antipsychotics [2] .
For example in the current study, 13 (29.5%) of those who had hyperkinetic disorder were given antipsychotics in the course of management while half of the 44 patients with CD equally had antipsychotics. Nevertheless, only one 1 patient had co-occurring psychosis and CD, while none had hyperkinetic disorder and psychosis. It is therefore possible that these disorders were previously misdiagnosed, hence the reason for being given antipsychotic trial.
Depot antipsychotic (flupenthixol) was used in three (4.9%) cases as in a previous study [2] , but was restricted to older teens who had compliance issues, though it has not been licensed for use below the age of 18 years [2] . Benzodiazepines (which was used for sleep problems) prescribing was exclusively off-label, accounting for 11.6%
of psychotropic use in the current study similar to a report from the United Kingdom [2] . Psychotropic medications e.g., antipsychotics
and benzodiazepines have been used for various purposes for which they are not approved in psychiatry with good results. These include agitation, aggression,obsessive compulsive disorder, posttraumatic stress disorder and sleep problems [2, 7, 8] . There is therefore a need for more research into other potential benefits of psychotropic medications especially as it affect pediatric mental health.
Polypharmacy, defined as the prescription of two or more medications concurrently to a patient [9] , is another notable feature in our study, as 29.2% rate was found. This is not peculiar to our center as authors from the developed [2, 9, 10] and developing countries [13, 25] have reported an increasing trend of multidrug treatment among children with mental conditions. In this audit, the most common pharmacological pair were antipsychotics plus stimulants and anticonvulsants plus stimulants, while the most common three combinations were antipsychotic-anticonvulsant-stimulant. Albeit the rationale behind the clinical decisions concerning psychotropic coprescribing was not routinely documented, these combinations suggest that disorders which often presented with aggressiveness and externalizing behavioral symptoms are mostly responsible for polypharmacy in our setting as reported by an earlier author [10] .
Polypharmacy is sometimes associated with risks which include adverse effects of drug interactions and increased toxicity, especially when liver enzyme inhibitors are part of the combinations [9] . This practice may not necessarily be an improper prescribing pattern as it is useful in some clinical situations, such as, the treatment of adverse effect of another agent, co-existing condition e.g., seizure and psychosis, immediate relief of symptoms while waiting for the main medication to act and so on. A consensus statement issued by some
Psychiatrists in the United Kingdom rationalizes some cases of transitory polypharmacy, comprising making a gradual change from one psychotropic to another (Royal College of Psychiatrists, 1993) [9] . Moreover, one author is of the opinion that the "demerits of polypharmacy are not contained in 'where' the drugs are being used but in 'how' these drugs are being used" [9] , further buttressing the 
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